Last reviewed · How we verify
Asunaprevir (ASV)
Asunaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.
Asunaprevir is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins. Used for Chronic hepatitis C virus (HCV) infection, genotype 1b.
At a glance
| Generic name | Asunaprevir (ASV) |
|---|---|
| Also known as | BMS-650032 |
| Sponsor | Bristol-Myers Squibb |
| Drug class | HCV NS3/4A protease inhibitor |
| Target | HCV NS3/4A protease |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
Asunaprevir binds to and inhibits the HCV NS3/4A serine protease, an enzyme essential for processing the HCV polyprotein into functional viral proteins. By blocking this protease activity, the drug prevents viral replication and reduces HCV viral load. It was developed as part of direct-acting antiviral (DAA) combination regimens for chronic hepatitis C infection.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1b
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
- Elevated liver enzymes
Key clinical trials
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
- Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy
- Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea
- Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1 (PHASE3)
- Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual (PHASE3)
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |